Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2026)

Jazz Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $47.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 21.97% year-over-year to $47.3 million; the trailing twelve-month figure through Mar 2026 stood at $47.3 million (up 21.97% YoY), and the FY2025 full-year result was $50.9 million, up 30.72% from the prior year.
• Operating Leases for Q1 2026 stood at $47.3 million, down from $50.9 million in the prior quarter.
• The five-year high for Operating Leases was $83.1 million in Q1 2022, with the low at $38.8 million in Q1 2025.
• Average Operating Leases over 5 years is $61.4 million, with a median of $61.9 million recorded in 2023.
• Year-over-year, Operating Leases tumbled 56.03% in 2022 and surged 30.72% in 2025.
• Tracing JAZZ's Operating Leases over 5 years: stood at $71.8 million in 2022, then decreased by 17.56% to $59.2 million in 2023, then plunged by 34.25% to $38.9 million in 2024, then jumped by 30.72% to $50.9 million in 2025, then slipped by 7.07% to $47.3 million in 2026.
• The last three Operating Leases figures came in at $47.3 million (Q1 2026), $50.9 million (Q4 2025), and $53.4 million (Q3 2025), per Business Quant data.

Peer Comparison